The clinical utility of an SCN1A genetic diagnosis in infantile‐onset epilepsy
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Aim Genetic testing in the epilepsies is becoming an increasingly accessible clinical tool. Mutations in the sodium channel alpha 1 subunit (SCN1A) gene are most notably associated with Dravet syndrome. This is the first study to assess the impact of SCN1A testing on patient management from both carer and physician perspectives. Method Participants were identified prospectively from referrals to the Epilepsy Genetics Service in Glasgow and contacted via their referring clinicians. Questionnaires exploring the consequences of SCN1A genetic testing for each case were sent to carers and physicians. Results Of the 244 individuals contacted, 182 (75%) carried a SCN1A mutation. Carers of 187 (77%) patients responded (90 females, 97 males; mean age at referral 4y 10mo; interquartile range 9y 1mo). Of those participants whose children tested positive for a mutation, 87% reported that genetic testing was helpful, leading to treatment changes resulting in fewer seizures and improved access to therapies and respite care. Out of 187 physicians, 163 responded (87%), of whom 48% reported that a positive test facilitated diagnosis earlier than with clinical and electroencephalography data alone. It prevented additional investigations in 67% of patients, altered treatment approach in 69%, influenced medication choice in 74%, and, through medication change, improved seizure control in 42%. Interpretation In addition to confirming a clinical diagnosis, a positive SCN1A test result influenced treatment choice and assisted in accessing additional therapies, especially in the very young.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Discovery of Grounded Theory; Strategies for Qualitative Research
Glaser, B. G., Strauss, A. L., & Strutzel, E. (1968) · Nursing Research · doi:10.1097/00006199-196807000-00014 · Cited by 39,449
De Novo Mutations in the Sodium-Channel Gene SCN1A Cause Severe Myoclonic Epilepsy of Infancy
Claes, L., Del-Favero, J., Ceulemans, B., Lagae, L., Van Broeckhoven, C., & De Jonghe, P. (2001) · The American Journal of Human Genetics · doi:10.1086/320609 · Cited by 1,292
Mutations of SCN1A, encoding a neuronal sodium channel, in two families with GEFS+2
Escayg, A., MacDonald, B. T., Meisler, M. H., Baulac, S., Huberfeld, G., An-Gourfinkel, I., Brice, A., LeGuern, E., Moulard, B., Chaigne, D., et al. (2000) · Nature Genetics · doi:10.1038/74159 · Cited by 996
Chiron, C., Marchand, M., Tran, A., Rey, E., d'Athis, P., Vincent, J., Dulac, O., & Pons, G. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03157-3 · Cited by 568 · cited 1×
“Randomized controlled trials show that certain combinations of medication can improve seizure control in Dravet syndrome.(9,11) Our results, although descriptive in nature, confirm that a substantial number of both carers and clinicians observed an improvement in seizure control following medication change.”
ResultPrognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome
Brunklaus, A., Ellis, R., Reavey, E., Forbes, G. H., & Zuberi, S. M. (2012) · Brain · doi:10.1093/brain/aws151 · Cited by 366 · cited 1×
“However, it appears that genetic testing facilitates a confident clinical diagnosis of Dravet syndrome and its prognosis, allowing for a more focused therapeutic approach to the comorbidities of the syndrome.(21,22) Many parents and carers reported that having a clear ‘label’ helped access to multi-agency support.”
BackgroundSelf-citationComorbidities and predictors of health‐related quality of life in Dravet syndrome
Brunklaus, A., Dorris, L., & Zuberi, S. M. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.03129.x · Cited by 123 · cited 1×
“However, it appears that genetic testing facilitates a confident clinical diagnosis of Dravet syndrome and its prognosis, allowing for a more focused therapeutic approach to the comorbidities of the syndrome.(21,22) Many parents and carers reported that having a clear ‘label’ helped access to multi-agency support.”
BackgroundSelf-citation
Cited by
Scheffer, I. E., Berkovic, S., Capovilla, G., Connolly, M. B., French, J., Guilhoto, L., Hirsch, E., Jain, S., Mathern, G. W., Moshé, S. L., et al. (2017) · Epilepsia · doi:10.1111/epi.13709 · Cited by 5,054
“It is notable that a monogenic etiology may cause a spectrum of mild to severe epilepsies, such as SCN1A mutations, which are associated with Dravet syndrome and Genetic Epilepsy with Febrile Seizures Plus (GEFS+), and may have implications for treatment.(43,44) Understanding the phenotypic spectrum associated with mu…”
BackgroundSelf-citationThe genetic landscape of the epileptic encephalopathies of infancy and childhood
McTague, A., Howell, K. B., Cross, J. H., Kurian, M. A., & Scheffer, I. E. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00250-1 · Cited by 604
Self-citationScheffer, I. E., Berkovic, S., Capovilla, G., Connolly, M. B., French, J., Guilhoto, L., Hirsch, E., Jain, S., Mathern, G. W., Moshé, S. L., et al. (2019) · Journal of the Japan Epilepsy Society · doi:10.3805/jjes.37.6 · Cited by 512
Self-citationSymonds, J. D., Zuberi, S. M., Stewart, K., McLellan, A., O‘Regan, M., MacLeod, S., Jollands, A., Joss, S., Kirkpatrick, M., Brunklaus, A., et al. (2019) · Brain · doi:10.1093/brain/awz195 · Cited by 459
Self-citationWilmshurst, J. M., Gaillard, W. D., Vinayan, K. P., Tsuchida, T. N., Plouin, P., Van Bogaert, P., Carrizosa, J., Elia, M., Craiu, D., Jovic, N. J., et al. (2015) · Epilepsia · doi:10.1111/epi.13057 · Cited by 418
Self-citationWirrell, E. C., Laux, L., Donner, E., Jette, N., Knupp, K., Meskis, M. A., Miller, I., Sullivan, J., Welborn, M., & Berg, A. T. (2017) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2017.01.025 · Cited by 283
Incidence of Dravet Syndrome in a US Population
Wu, Y. W., Sullivan, J., McDaniel, S. S., Meisler, M. H., Walsh, E. M., Li, S. X., & Kuzniewicz, M. W. (2015) · Pediatrics · doi:10.1542/peds.2015-1807 · Cited by 248
Early-life epilepsies and the emerging role of genetic testing
Berg, A. T., Coryell, J., Saneto, R. P., Grinspan, Z. M., Alexander, J. J., Kekis, M., Sullivan, J. E., Wirrell, E. C., Shellhaas, R. A., Mytinger, J. R., et al. (2017) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2017.1743 · Cited by 156
“Definite 82 65 79 (71-87) 78 (67-86) 22 34 (23-45) 42 (28-56)”
InfluentialMakiello, P., Feng, T., Dunwoody, B., Steckler, F., Symonds, J., Zuberi, S. M., Dorris, L., & Brunklaus, A. (2023) · Epilepsia · doi:10.1111/epi.17531 · Cited by 26
Self-citation
Metadata
- Authors
- BRUNKLAUS, A., DORRIS, L., ELLIS, R., REAVEY, E., LEE, E., FORBES, G., APPLETON, R., CROSS, J. H., FERRIE, C., HUGHES, I., JOLLANDS, A., KING, M. D., LIVINGSTON, J., LYNCH, B., PHILIP, S., SCHEFFER, I. E., WILLIAMS, R., & ZUBERI, S. M.
- Venue
- Developmental Medicine & Child Neurology
- Publisher
- Wiley
- Published
- 2012-11-20
- Volume
- 55
- Issue
- 2
- Pages
- 154-161
- ISSN
- 0012-1622 (ISSN-L)
- 1469-8749
- OpenAlex
- W1983334701
- Cited by
- 71
- References
- 6
- FWCI
- 4.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.